This is the authors' abstract. We don't add key points for this paper.
Cytokine release syndrome (CRS) is a potentially life-threatening toxicity that can occur due to highlevel immune activation.CRS can be triggered non-specifically by T-cell engaging therapies administered to treat hematologic malignancies.[1][2][3] Clinical manifestations vary, from fever to more severe symptoms requiring hospitalization. 2 Although CRS severity is influenced by disease status and underlying histology, prediction of CRS risk is currently not possible.4 Identification of high-grade CRS risk factors is critical to inform decisions on patient management when administering T-cell engaging therapies.5 Glofitamab, a CD20 × CD3 T-cell engaging bispecific antibody with a novel 2:1 format, demonstrated high complete response rates with manageable safety in a phase 1/2 study (NP30179; NCT03075696) in patients with large B-cell lymphoma.6,7 CRS observed with glofitamab is typically Grade 1/2 by American Society for Transplantation and Cellular Therapy (ASTCT) criteria and is mostly confined to the first treatment cycle.4,8,9 Komanduri et al. outlined a model using 8 baseline factors (CRS-risk score [CRS-RS]) that accurately classified the risk of Grade ≥2 CRS after the first glofitamab dose.10 Patients classified as low-risk (CRS-RS <5, 60% of the cohort) had a 5% chance of experiencing Grade ≥2 CRS (negative predictive value [NPV] 0.95; standard error [SE] 0.03).10 In aggressive non-Hodgkin lymphomas (aNHL), the parameters requiring assessment of bone marrow infiltration, peripheral blood infiltration, and cardiac comorbidities could be excluded from CRS-RS thereby offering improved clinical applicability without compromising performance.We report a streamlined model using 5 baseline factors (CRS-RS.5p)derived from the original CRS-RS (Table 1).To determine whether CRS-RS.5pcould accurately predict Grade ≥2 CRS events after the first glofitamab dose (step-up dosing [SUD], 2.5/10/30 mg), we compared CRS-RS.5p with CRS-RS in the NP30179 data set and then subsequently analyzed CRS-RS.5pperformance in both NP30179 and the GO43921 non-interventional study (NIS). Model parameters and risk classificationFor CRS-RS and CRS-RS.5p, to predict the risk of developing Grade ≥2 CRS, a multivariate model including the first glofitamab dose and a weighted sum of baseline, clinical, laboratory, and imaging parameters based on disease and CRS pathophysiology was used (Table 1).10 Weights reflected the predictive strength of risk factors in a dose-adjusted logistic regression model and the relative stability of risk parameters in a multivariate model resulting from random forest analysis.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Gritti et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: